Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ofranergene obadenovec - Notable Labs

Next Previous
X
Search
Drug Profile

Ofranergene obadenovec - Notable Labs

Alternative Names: GT-111; ofra-vec; VB 111

Latest Information Update: 04 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vascular Biogenics
  • Developer Gynecologic Oncology Group; Massachusetts General Hospital; National Cancer Institute (USA); Notable Labs
  • Class Antineoplastics; Gene therapies; Immunotherapies
  • Mechanism of Action Angiogenesis modulating agents; Gene transference; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Colorectal cancer; Glioblastoma; Lung cancer; Malignant melanoma; Ovarian cancer; Thyroid cancer

Most Recent Events

  • 04 Sep 2024 VBL Therapeutics terminated phase-II clinical trials in Glioblastoma (Late-stage disease, Second-line therapy or greater) in USA due to discontinuation of candidate(NCT04406272)
  • 02 Jun 2023 Efficacy and adverse events data from a phase III OVAL trial for Ovarian cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 31 Dec 2022 ofranergene obadenovec is no longer licensed to NanoCarrier in Japan

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top